What happened Healthcare giant Bausch Health (NYSE: BHC) outpaced a booming market last year as the stock jumped 62% compared to a 29% spike in the S&P 500 index, according to data provided by S&P Global Market Intelligence. The stock had been trailing the wider market as recently as October but rallied in the year's final weeks to post significant returns for shareholders. Image source: Getty Images. So what That rally was sparked by third-quarter results that in early November showed surprisingly strong sales gains. Organic revenue rose 4% thanks to robust demand in both of Bausch's main operating niches. Management at the time cited success with established drug brands like Xifaxan and recent launches including Lumify and Thermage. Now what The biopharma specialist raised its 2019 outlook in November and now sees full-year sales surpassing $8.5 billion. Some investors see that win as just the start of what could be a long period of outperformance for this arguably attractively priced stock with a deep pipeline of drugs and consumer healthcare products. Yet the stock's rally last year raises expectations, and so Bausch will have to continue impressing Wall Street with solid growth across its portfolio. 10 stocks we like better than Bausch Health CompaniesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bausch Health Companies wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Demitrios Kalogeropoulos has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies. The Motley Fool has a disclosure policy.Source